- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02235090
Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting
Assessment of Feasibility and Statistical Reliability of Functional Outcomes Measurement in Neuromuscular Patients Without Trial Site Visiting by Standard Functional Scales and by Special Autonomic Device in Double-blind, Placebo Controlled Study of Cervical Spinal Cord Transdermal Direct Current Stimulation in Patients With Spinal Muscular Atrophy
Clinical trials organization in several neuromuscular disorders (NMD) has some specific issues. Nonambulant status and difficulties with transportation are among them. Moreover a lot of patients with NMD have so poor condition that even short transportation is able to worse it. Such situation forces researchers to limit a region of recruitment for clinical trials and to exclude from trials more severe subgroup of patients, which cause additional issues especially for rare diseases.
The purpose of this study is to prove hypothesis about possibility to reliably monitor patient condition remotely, without trial site visiting. Visit-free study design is potentially able to widen eligible patient population and to decrease patient dropout rate as well as burden of numerous assessments. Meanwhile assessment frequency could be increased enabling monitoring of short fluctuations in patients' condition.
Spinal muscular atrophy (SMA) is a rare neuromuscular condition to which all mentioned above issues are completely applicable. Direct current stimulation (DCS) of neural structures is well studied and safe intervention, however, its effects on SMA patients' strength and durability has not been reported for today. The investigators suppose that investigation of DCS action in SMA patient population is an adequate model for visit-free design feasibility, reliability and sensitivity evaluation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kharkiv, Ukraine, 61068
- SI "Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- 5q SMA confirmed by molecular testing
Exclusion Criteria:
- Need for ventilation
- Hypersensitivity (pain or allergic reaction) to current stimulation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Zero-strength of direct current stimulation
Sham transdermal direct current stimulation of cervical spinal cord
|
10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
|
Experimental: 100 microamperes direct current stimulation
Transdermal direct current stimulation of cervical spinal cord
|
10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
|
Experimental: 1 milliampere direct current stimulation
Transdermal direct current stimulation of cervical spinal cord
|
10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Strength Changes from baseline measured by handheld myometry after spinal cord direct current stimulation of different intensity
Time Frame: Before and 0, 15, 30 minutes after spinal cord direct current stimulation
|
Before and 0, 15, 30 minutes after spinal cord direct current stimulation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Short time fluctuations of Hammersmith Functional Motor Scale indexes
Time Frame: Three times, three days consecutive measurement, every two months, assessed up to 6 months
|
Three times, three days consecutive measurement, every two months, assessed up to 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andriy V. Shatillo, MD, PhD, State Institution "Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine"
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSMA-INPN-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Muscular Atrophy
-
Marco CapogrossoRoche-GenentechRecruitingSpinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type 4United States
-
Institut de Myologie, FranceInstitut RocheCompletedType 2 Spinal Muscular Atrophy | Type 3 Spinal Muscular AtrophyBelgium, France, Germany
-
Marco CapogrossoRoche-GenentechNot yet recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy 4United States
-
Novartis Gene TherapiesActive, not recruitingSMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type I | Spinal Muscular Atrophy Type IIIUnited States, Belgium, France, Japan, United Kingdom, Italy, Taiwan, Australia, Canada
-
Hoffmann-La RocheRecruitingSpinal Muscular Atrophy (SMA)Belgium, United States, Croatia, Japan, Netherlands, Spain, Canada, Poland, United Kingdom, Italy, Portugal, Australia
-
Northwell HealthCompletedAdult Spinal Muscular AtrophyUnited States
-
Hugh McMillanFamilies of Spinal Muscular Atrophy; Gwendolyn Strong FoundationTerminatedSpinal Muscular Atrophy (SMA)Canada
-
Hoffmann-La RocheAssociation Française contre les Myopathies (AFM), ParisCompletedSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type III Non AmbulantGermany, Italy, France, Belgium, Poland, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalIstanbul UniversityRecruitingNeuromuscular Diseases | Spinal Muscular Atrophy Type 3Turkey
-
Washington University School of MedicineActive, not recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type IIUnited States, Canada
Clinical Trials on Direct current stimulation of cervical spinal cord
-
University of CincinnatiLindner Center of HOPE; Brain & Behavior Research FoundationCompletedMajor Depressive DisorderUnited States
-
Universidade Federal de PernambucoActive, not recruitingAtaxia, CerebellarBrazil
-
Northwell HealthPathMaker Neurosystems Inc.; Dr. Zaghloul AhmedCompletedStroke | Muscle Spasticity | Hemiparesis | Upper Extremity Paralysis | Spasticity as Sequela of Stroke | Cerebrovascular Accident (CVA)United States
-
Bronx VA Medical CenterNew York State Department of HealthCompletedSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Tetraplegia/TetraparesisUnited States
-
Lebanese American UniversityUnknown
-
University of LouisvilleWithdrawnSpinal Cord InjuriesUnited States
-
Max Planck Research Group Pain PerceptionEnrolling by invitation
-
Lee Fisher, PhDEnrolling by invitationCardiovascular Diseases | Stroke | Brain Diseases | Central Nervous System Diseases | Nervous System DiseasesUnited States
-
Istanbul Medeniyet UniversityCompletedMultiple Sclerosis | Transcranial Direct Current StimulationTurkey
-
Barts & The London NHS TrustBoston Scientific CorporationUnknown